Characterization of the peptide-binding specificity of Mamu-B*17 and identification of Mamu-B*17-restricted epitopes derived from simian immunodeficiency virus proteins

被引:84
作者
Mothé, BR
Sidney, J
Dzuris, JL
Liebl, ME
Fuenger, S
Watkins, DI
Sette, A
机构
[1] Univ Wisconsin, Wisconsin Reg Primate Res Ctr, Madison, WI 53715 USA
[2] Univ Wisconsin, Dept Pathol, Madison, WI 53715 USA
关键词
D O I
10.4049/jimmunol.169.1.210
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The SIV-infected rhesus macaque is an excellent model to examine candidate AIDS virus vaccines. These vaccines should elicit strong CD8(+) responses. Previous definition of the peptide-binding motif and optimal peptides for Mamu-A*01 has created a demand for Mamu-A*01-positive animals. We have now studied a second MHC class I molecule, Mamu-B*17, that is present in 12% of captive-bred Indian rhesus macaques. The peptide-binding specificity of the Mamu-B*17 molecule was characterized using single substitution analogs of two Mamu-B*17-binding peptides and libraries of naturally occurring sequences of viral or bacterial origin. Mamu-B*17 uses position 2 and the C terminus of its peptide ligands as dominant anchor residues. The C terminus was found to have a very narrow specificity for the bulky aromatic residue W, with other aromatic residues (F and Y) being only occasionally tolerated. Position 2 is associated with a broad chemical specificity, readily accommodating basic (H and R), bulky hydrophobic (F and M), and small aliphatic (A) residues. Using this motif, we identified 50 peptides derived from SIV(mac)239 that bound Mamu-B*17 with an affinity of 500 nM or better. ELISPOT and intracellular cytokine-staining assays showed that 16 of these peptides were antigenic. We have, therefore, doubled the number of MHC class I molecules for which SIV-derived binding peptides have been characterized. This allows for the quantitation of immune responses through tetramers and analysis of CD8(+) function by intracellular cytokine-staining assays and ELISPOT. Furthermore, it is an important step toward the design of a multiepitope vaccine for SIV and HIV.
引用
收藏
页码:210 / 219
页数:10
相关论文
共 65 条
[1]  
Allen T. G., 1999, Technical Bulletin - Maine Agricultural and Forest Experiment Station
[2]   Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication [J].
Allen, TM ;
Mortara, L ;
Mothé, BR ;
Liebl, M ;
Jing, PC ;
Calore, B ;
Piekarczyk, M ;
Ruddersdorf, R ;
O'Connor, DH ;
Wang, X ;
Wang, CX ;
Allison, DB ;
Altman, JD ;
Sette, A ;
Desrosiers, RC ;
Sutter, G ;
Watkins, DI .
JOURNAL OF VIROLOGY, 2002, 76 (08) :4108-4112
[3]   Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia [J].
Allen, TM ;
O'Connor, DH ;
Jing, PC ;
Dzuris, JL ;
Mothé, BR ;
Vogel, TU ;
Dunphy, E ;
Liebl, ME ;
Emerson, C ;
Wilson, N ;
Kunstman, KJ ;
Wang, XC ;
Allison, DB ;
Hughes, AL ;
Desrosiers, RC ;
Altman, JD ;
Wolinsky, SM ;
Sette, A ;
Watkins, DI .
NATURE, 2000, 407 (6802) :386-390
[4]   Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen [J].
Allen, TM ;
Vogel, TU ;
Fuller, DH ;
Mothé, BR ;
Steffen, S ;
Boyson, JE ;
Shipley, T ;
Fuller, J ;
Hanke, T ;
Sette, A ;
Altman, JD ;
Moss, B ;
McMichael, AJ ;
Watkins, DI .
JOURNAL OF IMMUNOLOGY, 2000, 164 (09) :4968-4978
[5]  
Allen TM, 1998, J IMMUNOL, V160, P6062
[6]   CD8+ lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule Mamu-A*01:: Implications for vaccine design and testing [J].
Allen, TM ;
Mothé, BR ;
Sidney, J ;
Jing, PC ;
Dzuris, JL ;
Liebl, ME ;
Vogel, TU ;
O'Connor, DH ;
Wang, XC ;
Wussow, MC ;
Thomson, JA ;
Altman, JD ;
Watkins, DI ;
Sette, A .
JOURNAL OF VIROLOGY, 2001, 75 (02) :738-749
[7]   Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif [J].
Altfeld, MA ;
Livingston, B ;
Reshamwala, N ;
Nguyen, PT ;
Addo, MM ;
Shea, A ;
Newman, M ;
Fikes, J ;
Sidney, J ;
Wentworth, P ;
Chesnut, R ;
Eldridge, RL ;
Rosenberg, ES ;
Robbins, GK ;
Brander, C ;
Sax, PE ;
Boswell, S ;
Flynn, T ;
Buchbinder, S ;
Goulder, PJR ;
Walker, BD ;
Sette, A ;
Kalams, SA .
JOURNAL OF VIROLOGY, 2001, 75 (03) :1301-1311
[8]  
Barber LD, 1997, J IMMUNOL, V158, P1660
[9]   HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VIF(-) MUTANT PARTICLES FROM RESTRICTIVE CELLS - ROLE OF VIF IN CORRECT PARTICLE ASSEMBLY AND INFECTIVITY [J].
BORMAN, AM ;
QUILLENT, C ;
CHARNEAU, P ;
DAUGUET, C ;
CLAVEL, F .
JOURNAL OF VIROLOGY, 1995, 69 (04) :2058-2067
[10]   T lymphocyte responses in HIV-1 infection: implications for vaccine development [J].
Brander, C ;
Walker, B .
CURRENT OPINION IN IMMUNOLOGY, 1999, 11 (04) :451-459